AddLife (ALIF-B.ST) Stock Analysis & AI Equity Report
AddLife (ALIF-B.ST) overview
AddLife (ALIF-B.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, AddLife reported revenue of SEK 10,286m and operating profit of SEK 721m; the year-end share price was 137.30 SEK and market capitalisation was SEK 16,732m. AddLife is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get AddLife's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-08-30. Data will be refreshed during report generation.
About AddLife
AddLife AB is a Swedish life science company active mainly in Europe. It owns and develops niche subsidiaries in two business areas, Labtech and Medtech, supplying products, solutions and services for healthcare, laboratories and research. Its offering includes medical technology, diagnostics, laboratory instruments, advisory services, product service and training.
Generate the AddLife report
AddLife is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for AddLife and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.